Dr Abhishek Tripathi speaks to ecancer about his review: "PARP Inhibitors in Prostate Cancer: A Promise Delivered".
He discusses the key points which surrounded the PROFOUND trial, looking at olaparib.
Dr Tripathi also outlines some of the current PARP inhibitors used for prostate cancer, as a well as some of the screening protocol in place for prostate cancer patients.
He explains the successes so far when using PARP inhibitors, and how the future looks for these drugs.
This programme has been supported by an unrestricted educational grant from Pfizer.